幹細胞治療の世界市場：2025年～2033年

幹細胞治療の世界市場は、2024年に164億4,000万米ドルに達し、2033年までには456億9,000万米ドルに達すると予測され、予測期間中の2025年から2033年のCAGRは12.7%で成長すると予測されています。

幹細胞治療は、様々な疾患や状態の予防、治療、管理のために幹細胞を用いる治療です。幹細胞は、筋肉、神経、血液細胞などの特殊な細胞に自己複製・分化できるユニークな未分化細胞です。幹細胞治療の第一の目標は、これらの細胞の再生特性を利用して、損傷した組織を修復または置換することであり、それによって、現在治療の選択肢が限られている疾患を持つ患者の健康状態を改善することです。

幹細胞には、患者自身の体から採取される自家幹細胞と、ドナーから採取される同種幹細胞があります。幹細胞治療は、再生医療における有望なフロンティアであり、幹細胞のユニークな特性を活用して複雑な健康課題に対処し、患者のQOLを向上させることを目指しています。研究が進むにつれ、この革新的なアプローチは、現在有効な治療法がない様々な疾患の治療において、大きな進歩をもたらす可能性を秘めています。このような要因が、幹細胞治療の世界市場拡大の原動力となっています。

市場力学：

促進要因と抑制要因

再生医療の進歩

再生医療の進歩は、幹細胞治療世界市場の成長促進要因であり、患者の転帰を向上させることを目的とした革新的な技術やテクノロジーの継続的な進化と統合です。この分野では、損傷を受けた組織や臓器の修復、置換、再生に焦点が当てられており、そのユニークな再生特性から幹細胞が頻繁に利用されています。

近年の調査により、幹細胞の分化能や本質的な修復メカニズムなど、幹細胞の生物学的性質に関する理解が著しく深まっています。この知識は、従来の医薬品では十分に対処できなかった慢性疾患や傷害を治療するために、幹細胞の再生能力を活用できる効果的な治療法を開発するために不可欠です。

CRISPRのような遺伝子編集技術の進歩は、組織工学の革新と並んで、治療目的で幹細胞を操作する能力を高めています。三次元オルガノイドやスキャホールドの開発により、自然の組織環境を模倣することで、より効果的な組織再生が可能になりました。こうした進歩により、患者一人ひとりのニーズに合わせた治療が可能となる個別化医療が実現します。

さらに、この業界の主要企業の技術的進歩やイノベーションは、この世界の幹細胞治療市場の成長を促進すると思われます。例えば、2024年7月、STEMCELL Technologiesは、細胞工学研究と様々な疾患に対する革新的な細胞療法の創出を促進することを目的とした革新的技術であるCellPore Transfection Systemを発表しました。このシステムは、細胞導入法の大きな進歩を意味します。

また、2024年1月、Therapeutic Solutions International, Inc.（TSOI）は、てんかんの治療を目的とした成体幹細胞治療の進展に焦点を当てた新しい子会社、Epilepsy Bio, Inc.の設立を発表しました。このイニシアチブは、てんかんという神経疾患の治療のための細胞および免疫学的戦略に関する知的財産と臨床的洞察を活用するというTSOIの広範な使命に沿ったものです。これらすべての要因が、世界の幹細胞治療市場に需要をもたらしています。

さらに、技術の進歩による成長に対する需要の高まりも、世界の幹細胞治療市場の拡大に寄与しています。

高い治療費

治療費の高騰は幹細胞治療の世界市場において大きな制約となっており、患者のアクセスや市場全体の成長に影響を与えています。幹細胞治療に伴う経済的負担は、その潜在的なメリットにもかかわらず、患者やヘルスケアプロバイダーの双方に、この革新的な治療への意欲を失わせる可能性があります。

DVCによると、幹細胞治療にかかる費用は様々な要因によって5,000ドルから50,000ドルの幅があるといいます。このようなばらつきは、患者やヘルスケアプロバイダーが、その潜在的な利益にもかかわらず、この革新的な治療を受けることを躊躇させる可能性があります。幹細胞治療には、特殊な機器や高度な訓練を受けた人材を必要とする複雑な手順が伴うことが多いです。

幹細胞を採取し、加工し、投与することに関連するコストは、相当なものになる可能性があります。例えば、基本的な関節注射であれば1,000ドル程度で済みますが、より複雑な治療の場合、その内容にもよりますが10万米ドルを超えることもあります。したがって、上記のような要因が、世界の幹細胞治療市場の潜在的成長を制限している可能性があります。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 再生医療の進歩
  • 抑制要因
    • 高額な治療費
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 特許分析
• 規制分析
• SWOT分析
• アンメットニーズ

第6章 治療タイプ別

• 自家幹細胞治療
• 同種異系幹細胞治療

第7章 細胞源別

• 脂肪組織由来間葉系幹細胞
• 骨髄由来間葉系幹細胞
• 臍帯血/胚性幹細胞
• その他

第8章 治療用途別

• 筋骨格障害
• 神経疾患
• 自己免疫疾患
• 心血管疾患
• 傷・手術
• 炎症性
• その他

第9章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • スペイン
  • イタリア
  • その他欧州地域
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋
• 中東・アフリカ

第10章 競合情勢

• 競合シナリオ
• 市況・シェア分析
• M&A分析

第11章 企業プロファイル

• Mesoblast Ltd
  • 会社概要
  • 製品ポートフォリオ
    • 製品説明
    • 製品の主要業績評価指標（KPI）
    • 過去および予測の製品販売
    • 製品販売量
  • 財務概要
    • 企業収益
    • 地域別収益分配
    • 収益予測
  • 主な発展
    • 合併と買収
    • 主な製品開発活動
    • 規制当局の承認等
  • SWOT分析
• Lineage Cell Therapeutics, Inc.
• BlueRock Therapeutics LP
• Orchard Therapeutics plc.
• Vericel Corporation.
• CRISPR Therapeutics AG
• Fate Therapeutics, Inc.
• Novartis AG
• Bristol Myers Squibb（Juno Therapeutics, Inc.）
• Bluebird Bio, Inc.
• MEDIPOST Co., Ltd.
• ANTEROGEN.CO.,LTD.
• CORESTEMCHEMON Inc.
• PHARMICELL Co., Ltd
• JCR Pharmaceuticals Co., Ltd.

第12章 付録

The global stem cell therapy market reached US$ 16.44 billion in 2024 and is expected to reach US$ 45.69 billion by 2033, growing at a CAGR of 12.7 % during the forecast period 2025-2033.

Stem cell therapy is a medical treatment that employs stem cells to prevent, treat, or manage a variety of diseases and conditions. Stem cells are unique, undifferentiated cells capable of self-renewal and differentiation into specialized cell types, such as muscle, nerve, or blood cells. The primary goal of stem cell therapy is to harness the regenerative properties of these cells to repair or replace damaged tissues, thereby improving health outcomes for patients with conditions that currently have limited treatment options.

Types of stem cells include autologous stem cells which are harvested from the patient's own body and allogeneic stem cells which are sourced from a donor. Stem cell therapy represents a promising frontier in regenerative medicine, aiming to leverage the unique properties of stem cells to address complex health challenges and enhance patient quality of life. As research progresses, this innovative approach holds the potential for significant advancements in treating a variety of conditions that currently lack effective therapies. These factors have driven the global stem cell therapy market expansion.

Market Dynamics: Drivers & Restraints

Advancements in Regenerative Medicine

Advancements in regenerative medicine are a crucial driver of growth in the global stem cell therapy market, the ongoing evolution and integration of innovative techniques and technologies aimed at enhancing patient outcomes. This field focuses on repairing, replacing, or regenerating damaged tissues and organs, frequently utilizing stem cells due to their unique regenerative properties.

Recent research has significantly improved our understanding of stem cell biology, including their differentiation capabilities and intrinsic repair mechanisms. This knowledge is essential for developing effective therapies that can leverage the regenerative potential of stem cells to treat chronic diseases and injuries that traditional pharmaceuticals cannot adequately address.

Advances in gene editing technologies, such as CRISPR, alongside innovations in tissue engineering, have enhanced the ability to manipulate stem cells for therapeutic purposes. The development of three-dimensional organoids and scaffolds allows for more effective tissue regeneration by mimicking natural tissue environments. These advancements enable personalized medicine approaches, where treatments can be tailored to individual patient needs.

Furthermore, key players in the industry's technological advancements and innovations would drive this global stem cell therapy market growth. For instance, in July 2024, STEMCELL Technologies introduced the CellPore Transfection System, an innovative technology aimed at advancing cell engineering research and the creation of innovative cell therapies for various diseases. This system signifies a major advancement in cellular delivery methods.

Also, in January 2024, Therapeutic Solutions International, Inc. (TSOI) announced the formation of Epilepsy Bio, Inc., a new subsidiary focused on advancing adult stem cell therapies aimed at curing epilepsy. This initiative aligns with TSOI's broader mission to utilize its intellectual property and clinical insights related to cellular and immunological strategies for treating this neurological condition. All these factors demand the global stem cell therapy market.

Moreover, the rising demand for the growth of advancements in technology contributes to the global stem cell therapy market expansion.

High Treatment Costs

High treatment costs are a significant constraint in the global stem cell therapy market, affecting patient access and overall market growth. The financial burden associated with stem cell therapies can discourage both patients and healthcare providers from pursuing these innovative treatments, despite their potential benefits.

According to the DVC, stem data stated that the costs associated with stem cell therapies can vary widely, ranging from $5,000 to USD 50,000, depending on various factors. This variability can deter patients and healthcare providers from pursuing these innovative treatments, despite their potential benefits. Stem cell therapies often involve intricate procedures that require specialized equipment and highly trained personnel.

The costs associated with harvesting, processing, and administering stem cells can be substantial. For instance, basic joint injections may cost up to $1,000, while more complex treatments can exceed $100,000, depending on the specifics of the therapy. Thus, the above factors could be limiting the global stem cell therapy market's potential growth.

Segment Analysis

The global stem cell therapy market is segmented based on therapy type, cell source, therapeutic application, and region.

Therapy Type:

The allogeneic stem cell therapy segment is expected to dominate the global stem cell therapy market share

The allogeneic stem cell therapy segment holds a major portion of the global stem cell therapy market share and is expected to continue to hold a significant portion of the global stem cell therapy market share during the forecast period.

Allogeneic stem cell therapy is a critical segment of the global stem cell therapy market, involving the use of stem cells obtained from a donor to treat various medical conditions, particularly blood disorders and cancers. This approach differs from autologous stem cell therapy, where the patient's cells are utilized. Allogeneic stem cell therapy relies on stem cells sourced from a donor, which can be either a related individual (such as a sibling) or an unrelated person. The ideal donor typically has a compatible tissue type, defined by human leukocyte antigens (HLAs). If no suitable family member is available, donors can be identified through bone marrow registries.

The allogeneic segment of stem cell therapy is gaining popularity due to its scalability and "off-the-shelf" availability. Unlike autologous therapies that require time-consuming cell collection and processing from individual patients, allogeneic therapies can be prepared in advance from healthy donors and stored for immediate use. This aspect significantly enhances accessibility for patients in urgent need of treatment.

Furthermore, key players in the industry product launches & approvals that would drive this segment growth in the global stem cell therapy market. For instance, in April 2023, the U.S. Food and Drug Administration (FDA) approved Omisirge (generic name: omidubicel-onlv), a modified allogeneic cord blood-based cell therapy designed to expedite the recovery of neutrophils, a critical type of white blood cell essential for fighting infections. This therapy is intended for adults and pediatric patients aged 12 years and older who have blood cancers and are scheduled to undergo umbilical cord blood transplantation following a myeloablative conditioning regimen, which typically includes treatments such as chemotherapy or radiation.

Also, in September 2024, Poseida Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to P-BCMA-ALLO1, an investigational allogeneic CAR-T cell therapy based on stem cell memory T cells (TSCM). This therapy is currently in Phase 1/1b clinical development for treating patients with relapsed or refractory multiple myeloma, a challenging type of blood cancer. These factors have solidified the segment's position in the global stem cell therapy market.

Geographical Analysis

North America is expected to hold a significant position in the global stem cell therapy market share

North America holds a substantial position in the global stem cell therapy market and is expected to hold most of the market share. The rise in chronic conditions, including cancer, cardiovascular diseases, and musculoskeletal disorders, significantly boosts the demand for stem cell therapies.

The demographic shift towards an older population is contributing to the demand for regenerative medicine. Projections suggest that the number of adults aged 65 and older will increase from approximately 56 million in 2020 to 73 million by 2030, creating a heightened need for treatments targeting age-related health issues. There has been significant investment in stem cell research, exceeding $12 billion in 2023, which is fostering innovation and development in this field. The number of clinical trials has risen by 28% annually, indicating a robust pipeline of new therapies.

Furthermore, advancements in manufacturing and preservation technologies are enhancing the viability and application of stem cell therapies. The Regenerative Medicine Advanced Therapy (RMAT) designation is an important regulatory framework established by the FDA as part of the 21st Century Cures Act. This designation is designed to accelerate the development and review processes for regenerative medicine therapies, including stem cell therapies, that are intended to treat serious or life-threatening conditions.

Moreover, a major number of key players are present, research activities, and product launches & approvals that would drive this global stem cell therapy market. For instance, in November 2024, the University of Texas MD Anderson Cancer Center launched the Institute for Cell Therapy Discovery & Innovation, an initiative focused on advancing impactful cell therapies for a range of conditions, including cancer and autoimmune diseases. This initiative underscores MD Anderson's commitment to leading the field of cell therapy.

Also, in November 2024, GIOSTAR (Global Institute of Stem Cell Therapy and Research) announced that it had received FDA clearance for its Investigational New Drug (IND) application, allowing the company to begin a Phase 2 clinical trial for its innovative stem cell therapy targeting Type II diabetes. This therapy, known as DT2-SCT, utilizes autologous mesenchymal stem cells sourced from the patient's visceral tissues to mitigate the systemic effects of diabetes. Thus, the above factors are consolidating the region's position as a dominant force in the global stem cell therapy market.

Asia Pacific is growing at the fastest pace in the global stem cell therapy market share

Asia Pacific holds the fastest pace in the global stem cell therapy market and is expected to hold most of the market share.

The region's large and aging population contributes to an increased prevalence of age-related diseases such as diabetes, cardiovascular diseases, and neurodegenerative disorders. This demographic shift drives the demand for regenerative therapies that can improve health outcomes in older adults. The growing incidence of chronic diseases, including diabetes, cardiovascular diseases, and Alzheimer's disease, significantly boosts the demand for stem cell therapies as potential treatments that can alleviate symptoms or reverse disease progression.

There is a rising need for advanced medical therapies, particularly those utilizing stem cells to address complex health issues. This demand is primarily fueled by the necessity for effective treatments for chronic diseases and conditions that currently lack sufficient therapeutic options.

As public understanding of the benefits and potential of stem cell therapies expands, more patients and healthcare providers are recognizing these treatments as viable options for managing various health conditions. The Asia-Pacific region has sophisticated medical facilities and technology that support the development and application of stem cell therapies. Countries like China and India are making substantial investments in healthcare infrastructure, enhancing research and clinical applications.

Furthermore, major players in the industry have key initiatives and awareness programs that would drive this global stem cell therapy market growth. For instance, in July 2024, Bioserve India introduced a new line of advanced stem cell products designed to enhance scientific research and drug development in the Indian market. This launch is part of a comprehensive strategy aimed at fostering progress in regenerative medicine and therapeutic discovery, underscoring the increasing significance of stem cell technology across various medical disciplines.

Also, in June 2024, a new free stem cell treatment program was launched specifically for elderly women, aimed at addressing health issues commonly associated with aging. This initiative reflects a growing recognition of the potential benefits of stem cell therapies in improving health outcomes and quality of life for older populations. Thus, the above factors are consolidating the region's position as the fastest-growing force in the global stem cell therapy market.

Competitive Landscape

The major global players in the stem cell therapy market include Mesoblast Ltd, Lineage Cell Therapeutics, Inc., BlueRock Therapeutics LP, Orchard Therapeutics plc., Vericel Corporation., CRISPR Therapeutics AG, Fate Therapeutics, Inc., Novartis AG, Bristol Myers Squibb (Juno Therapeutics, Inc.), Bluebird bio, Inc., MEDIPOST Co., Ltd., ANTEROGEN.CO., LTD., CORESTEMCHEMON Inc., PHARMICELL Co., Ltd, and JCR Pharmaceuticals Co., Ltd. among others.

Key Developments

• In November 2024, Vertex Pharmaceuticals launched a pivotal Phase 1/2 clinical trial for its experimental stem cell-derived islet therapy, named VX-264, targeting patients with Type 1 diabetes (T1D). This trial represents a crucial advancement in the development of innovative therapies that have the potential to revolutionize diabetes treatment.
• In February 2024, Kenai Therapeutics, a biotechnology company based in San Diego, successfully raised $82 million in Series A financing to advance its development of cell therapies targeting Parkinson's disease and other nervous system disorders. This funding round was co-led by Cure Ventures, the Alaska Permanent Fund Corporation, and The Column Group, with additional participation from Euclidean Capital and Saisei Ventures.

Why Purchase the Report?

• Pipeline & Innovations: Reviews ongoing clinical trials, and product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
• Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
• Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
• Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
• Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
• Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
• Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
• Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
• Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
• Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
• Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
• Post-market Surveillance: Uses post-market data to enhance product safety and access.
• Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global stem cell therapy market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

• Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
• Regulatory & Policy: Compliance Officers, Government, Health Economists, and Market Access Specialists.
• Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
• Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
• Consulting & Advisory: Healthcare Consultants, Industry Associations, and Analysts.
• Supply Chain: Distribution and Supply Chain Managers.
• Consumers & Advocacy: Patients, Advocacy Groups, and Insurance Companies.
• Academic & Research: Academic Institutions.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Therapy Type
• 3.2. Snippet by Cell Source
• 3.3. Snippet by Therapeutic Application
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Advancements in Regenerative Medicine
  • 4.1.2. Restraints
    • 4.1.2.1. High Treatment Costs
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Patent Analysis
• 5.5. Regulatory Analysis
• 5.6. SWOT Analysis
• 5.7. Unmet Needs

6. By Therapy Type

• 6.1. Introduction
  • 6.1.1. Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 6.1.2. Market Attractiveness Index, By Therapy Type
• 6.2. Autologous Stem Cell Therapy*
  • 6.2.1. Introduction
  • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 6.3. Allogeneic Stem Cell Therapy

7. By Cell Source

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
  • 7.1.2. Market Attractiveness Index, By Cell Source
• 7.2. Adipose Tissue-Derived Mesenchymal Stem Cells*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Bone Marrow-Derived Mesenchymal Stem Cells
• 7.4. Cord Blood/Embryonic Stem Cells
• 7.5. Others

8. By Therapeutic Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 8.1.2. Market Attractiveness Index, By Therapeutic Application
• 8.2. Musculoskeletal Disorders*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Neurological Disorders
• 8.4. Autoimmune Diseases
• 8.5. Cardiovascular Diseases
• 8.6. Wounds & Surgeries
• 8.7. Inflammatory
• 8.8. Others

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.6.1. U.S.
    • 9.2.6.2. Canada
    • 9.2.6.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.6.1. Germany
    • 9.3.6.2. U.K.
    • 9.3.6.3. France
    • 9.3.6.4. Spain
    • 9.3.6.5. Italy
    • 9.3.6.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.6.1. Brazil
    • 9.4.6.2. Argentina
    • 9.4.6.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application
  • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.6.1. China
    • 9.5.6.2. India
    • 9.5.6.3. Japan
    • 9.5.6.4. South Korea
    • 9.5.6.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapy Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cell Source
  • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Application

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Mesoblast Ltd*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio
    • 11.1.2.1. Product Description
    • 11.1.2.2. Product Key Performance Indicators (KPIs)
    • 11.1.2.3. Historic and Forecasted Product Sales
    • 11.1.2.4. Product Sales Volume
  • 11.1.3. Financial Overview
    • 11.1.3.1. Company Revenue
    • 11.1.3.2. Geographical Revenue Shares
    • 11.1.3.3. Revenue Forecasts
  • 11.1.4. Key Developments
    • 11.1.4.1. Mergers & Acquisitions
    • 11.1.4.2. Key Product Development Activities
    • 11.1.4.3. Regulatory Approvals etc.
  • 11.1.5. SWOT Analysis
• 11.2. Lineage Cell Therapeutics, Inc.
• 11.3. BlueRock Therapeutics LP
• 11.4. Orchard Therapeutics plc.
• 11.5. Vericel Corporation.
• 11.6. CRISPR Therapeutics AG
• 11.7. Fate Therapeutics, Inc.
• 11.8. Novartis AG
• 11.9. Bristol Myers Squibb (Juno Therapeutics, Inc.)
• 11.10. Bluebird Bio, Inc.
• 11.11. MEDIPOST Co., Ltd.
• 11.12. ANTEROGEN.CO.,LTD.
• 11.13. CORESTEMCHEMON Inc.
• 11.14. PHARMICELL Co., Ltd
• 11.15. JCR Pharmaceuticals Co., Ltd.

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us